SARS–CoV–2 

As of December 20, 2024 the CDC and NIH noted that work with SARS-CoV-2 can now be conducted at a minimum in BSL2 containment provided a risk assessment does not warrant continuing work in BSL3 containment. When determining the most suitable biocontainment level, risk assessment considerations include the specific strain(s) being used, titer, animal model, risk of aerosolization, and other factors.

This update does not change the BSL3 containment requirements for SARS-CoV and Middle East Respiratory Syndrome (MERS-CoV).

Accordingly, when submitting an IBC protocol involving experiments with SARS-CoV-2, investigators are now required to propose a suitable biocontainment level (BSL2 or BSL3, ABSL2 or ABSL3) determined by risk assessment.

Please see the following references:

• CDC: Laboratory Biosafety Guidelines for working with SARS-CoV-2
• NIH: Biosafety Considerations for Research Involving SARS-CoV-2
• WHO: Laboratory biosafety guidance related to SARS-CoV-2 (COVID-19)
• ABSA International:  SARS-CoV-2/COVID-19 Toolbox

Please contact Jenni Kershner if you have any questions or concerns during this transition.